The plasmin-generating system controls, to a great extent, the degree of connective tissue destruction as well as fibrin deposition-two contributors to the pathogenesis generated in diseases such as rheumatoid arthritis. Vitronectin, an adhesive blood glycoprotein, has the potential to modulate this system by its known capacity to interact with plasminogen activator inhibitor-1, plasminogen activators, the urokinase plasminogen activator receptor, and plasminogen. The net effect of these interactions, in terms of plasmin generation, is not known as yet. In the present study, we have investigated the possible expression and role of vitronectin in rheumatoid arthritic synovia. Analysis of synovial frozen sections by immunofluorescence showed the presence of vitronectin in the 13 cases studied. In situ hybridization analysis demonstrated the presence of vitronectin mRNA in cells present in areas rich in infiltrating inflammatory cells. The adherent population of the rheumatoid arthritic synovial cells was isolated and found to synthesize and secrete vitronectin into the medium (seven of 10 isolates), as assessed by metabolic labelling and immunoprecipitation. Plasmin-generating activity was detected in the adherent synovial cells, and this activity was increased by antibodies to vitronectin. Our findings show, for the first time, that vitronectin can be endogenously produced in a pathophysiological system where it can inhibit the generation of plasmin.
R arthritis is a systemic inflammatory disa few exceptions, most cell types, other than hepatocytes/hepatoma cells, do not synthesize vitronectin in ease characterized by synovial tissue hyperplasia, connective tissue destruction, and increased leucocyte culture [20, 21] . The present study was undertaken to investigate infiltration fostered, in part, by fibrin deposits [1] . The extensive connective tissue destruction observed in whether vitronectin is expressed, and/or deposited, in inflammatory conditions, such as rheumatoid arthritis, rheumatoid arthritis is largely due to the activity of latent metalloproteinases, some of which are activated and to determine its role in relation to plasminogen activation. Previous studies of the various processes by plasmin, the enzyme which is also responsible for the degradation of numerous connective tissue glycoinvolving the interaction of vitronectin with PAI-1 have been performed using exogenously added purified proteins, as well as for the degradation of fibrin [2, 3] .
Plasmin is derived from the zymogen plasminogen, vitronectin, or vitronectin present in the fetal calf serum used in tissue culture. Our study shows, for the through the actions of plasminogen activators, of which there are two types: tissue/blood vessel type first time, that endogenously produced vitronectin inhibits plasmin generation in a pathophysiological plasminogen activator (tPA) and urokinase plasminogen activator (uPA). Plasminogen activators are, in system akin to that found in vivo. turn, controlled primarily by plasminogen activator inhibitor-1 (PAI-1). PAI-1 is present in blood [4] , and METHODS can be synthesized by a variety of cell types [5, 6 ] . Its Antibodies activity is maintained by binding to vitronectin [7] [8] [9] [10] .
The monoclonal antibody to vitronectin, MaVN, In addition to maintaining PAI-1 activity, the vitronecpreviously referred to as MaSp (IgG1, purchased from tin-PAI-1 interaction can inhibit cell adhesion via the Quidel, San Diego, CA, USA) and the rabbit antiintegrin a v b 3 [11] or via the uPA receptor [12] . The human vitronectin ( Telios Pharmaceuticals, La Jolla, net effect of the latter interactions, in terms of plasmin-CA, USA) have been characterized previously [21] . generating activity, has not been studied as yet.
The anti-vitronectin antiserum was adsorbed on bovine Vitronectin is an adhesion-promoting glycoprotein serum-Sepharose and affinity purified on human [13] which is found primarily in blood; it has also vitronectin-Sepharose. The monoclonal antibody to been immunohistochemically localized extravascularly, fibronectin (3E3) was from Telios Pharmaceuticals. mostly deposited in diseased connective tissues [14] [15] [16] [17] .
Fibrin was detected with monoclonal antibody E8 Its primary site of synthesis is the liver [18, 19] ; with (Immunotech, Marseille, France) which recognizes fibrin and not fibrinogen. The monoclonal antibody to PAI-1 (MAI-11, IgG1; [22] ) and the goat anti-human USA). The anti-CD68 macrophage marker (clone fibroblasts. The human foreskin fibroblasts AG1518 were obtained from ATCC (Rockville, MD, USA). M718) and the monoclonal antibody recognizing HLA-DR were obtained from Dakopatts (Glostrup, Denmark). The monoclonal antibody RFD7 is part of
In situ hybridization Biopsies from synovectomies were cryosectioned, the RF series of macrophage markers [23] . The rabbit anti-rat fibronectin IgG has previously been described fixed with 4% paraformaldehyde and stored in 70% ethanol at 4°C. In situ hybridization was carried out [24] . The monoclonal antibodies to smooth muscle actin, to prolyl hydroxylase, to human fibroblast suressentially as described previously [25] . The probes utilized were: a 1.5 kb polymerase chain reaction face protein (clone IB10), and the control mouse and rabbit IgG were obtained from Sigma (St Louis, (PCR)-generated cDNA from HepG2 cells [21] encoding the full human vitronectin, sequence and a collagen MO, USA).
a1(I ) 372 bp human cDNA probe [25] Fluorescence microscopy and photography were perexposure, the slides were developed by immersion in Dektol ( Kodak) at 15°C for 2 min, followed by fixation formed on a Nikon microscope with a microphotography attachment.
for 5 min (Polymax, Kodak) and washing in water for 5 min; they were then counterstained with haematoxylin and eosin, and mounted. Control slides included: Rheumatoid arthritic synovial cell isolation and cell culture (1) the use of a collagen probe as (a) a negative control for hybridization of mRNA from myeloid cells and Tissues were minced and treated with a solution of collagenase/DNAase as follows: 2 mg/ml collagenase (b) as a positive control for hybridization to stromal cells; (2) frozen sections of liver known to express type IV (Sigma), 140 mg/ml DNAase (Sigma) in RPMI (Gibco, Gaithersburg, MD, USA) containing 10% fetal vitronectin, used as a positive control for the vitronectin probe; and (3) pre-treatment with RNase prior to calf serum ( FCS) (National Veterinary Institute, Uppsala, Sweden), 25 m HEPES (Gibco), 4 m gluthybridization in order to check that the probes were hybridized with cellular RNA in the tissue. amine, 120 mg/ml penicillin and 100 mg/ml streptomycin, while shaking at 37°C for 2 h. The resulting cell suspensions were passed through a metal sieve to
Metabolic labelling and immunoprecipitation
Rheumatoid arthritic synovial cells (1 to 3 × 106) remove large aggregates; the cell suspensions were centrifuged at 1000 r.p.m. and the pellet resuspended were plated for 1 h in the presence of 10% FCS. The medium was removed and the cell monolayer was in the above RPMI solution, without enzymes. Cells were then plated in the presence of 10% FCS for 1-2 h washed twice with phosphate-buffered saline (PBS ). Methionine/cysteine-free MCDB medium (Swedish at 37°C. The unattached cells were discarded, and the attached cells were trypsinized and either replated for Veterinary Institute), containing 4 m glutamine, 10 m HEPES, 2% dialysed FCS, 120 mg/ml penicillin, further study over a period of 24 h, or preserved frozen in liquid nitrogen. The adherent cell population was 100 mg/ml streptomycin and 50 mCi/ml [35S]methionine/ cysteine (Amersham, UK ), was added and cells were mostly composed of myeloid cells and fibroblasts. In three cases, rheumatoid arthritic synovial cells were incubated for 16 h at 37°C. The medium was removed, treated with 2 m phenylmethylsulphonyl fluoride cultured during a period of at least 2 weeks and passaged at least three times in order to obtain synovial (PMSF ) (Sigma), spun to remove cell debris, and concentrated by the addition of 70% ammonium of plasmin in the absence or presence of antibodies to vitronectin and PAI-1 (both are of isotype IgG1), sulphate while mixing at 10°C for 1-3 h. Following centrifugation at 4000 r.p.m. for 40 min at 10°C, the (2) the test of conditioned medium without cells in the absence or presence of antibodies, prior to the addition pellet was resuspended in a minimum volume of Trisbuffered saline ( TBS ) and dialysed against TBS for of plasminogen, to test the requirement for cell surfaces for the generation of plasmin; and (3) the omission of 2-5 h at 10°C.
Attached cells were extracted by addition of 1 ml plasminogen in wells containing antibodies to test for possible extraneous reactivities between the antibodies of 0.5% deoxycholate (DOC; Merck, Darmstadt, Germany), 0.5% NP-40, 0.2% SDS (BDH Ltd, Poole) , and the plasmin substrate. EDTA for 10 min on ice, followed by scraping and RESULTS centrifugation at 12 000 r.p.m. for 10 min. The detergent-soluble extract and the conditioned medium were Table I shows the distribution of vitronectin in rheumatoid synovia. Immunofluorescence analysis of pre-cleared for immunoprecipitation by the addition of non-immune rabbit serum followed by Protein synovia showing no signs of inflammation showed only weak and diffuse staining for vitronectin. In contrast, A-and/or Protein G-Sepharose or anti-mouse IgG 1 -Sepharose (Pharmacia, Uppsala, Sweden). Preanalysis of rheumatoid arthritic synovial tissues demonstrated the presence of vitronectin in all the cases cleared supernatants were incubated with the appropriate antibodies at 10°C, for~16 h, followed by studied (n = 13). Vitronectin was found either deposited in granulation tissue (Fig. 1) or cellularly associincubation with Protein A-or G-Sepharose for 1 h. Following centrifugation, the pellets were washed twice ated ( Fig. 2) . In some cases, where there was no granulation tissue, vitronectin was present in fibrillar with 0.5% DOC, 0.5% Triton X-100 (Merck), 0.1% SDS in TBS, twice with 0.5% Triton X-100, 0.5  form in the stroma (not shown).
The staining for vitronectin shown in Figs 1 and 2 NaCl in TBS, and once with 0.15% Triton X-100 in TBS. Electrophoresis sample buffer, with 10 m was performed with affinity-purified polyclonal antibodies to vitronectin. This staining was identical to b-mercaptoethanol, was added to the pellets and heated to 95°C for 10 min. The samples were then analysed that obtained with the monoclonal antibody MaVN. Figure 1 shows the double-immunofluorescence pattern on 7.5% gels by SDS-PAGE and followed by autoradiography.
of an area stained for vitronectin (Fig. 1a) , and fibrin (Fig. 1b) , demonstrating a staining representative of granulation tissue areas. PAI-1 was associated with Assay for plasmin-generating activity Rheumatoid arthritic synovial cells or fibroblasts cells present in granulation tissue ( Fig. 1c) , and was also found associated with blood vessels, but similar (3 × 104 cells/well ) were plated in duplicate in 96-well tissue culture-treated plates and incubated in either to vitronectin, PAI-1 was not present in undamaged areas of the connective tissue (not shown). Figure 1d RPMI or MCDB containing 0.2% BSA and 10 m HEPES for 1-2 h, before the addition of antibodies in shows the staining obtained with non-immune rabbit IgG. the appropriate wells. Polyclonal and monoclonal antibodies were used at 80 and 50 mg/ml, respectively. The cells were then incubated overnight and plasminogen Fig. 1 .
to calculate the levels of significance (P values) of the Cellular, representative staining is shown in Fig. 2 . Treatment with control rabbit polyclonal antibodies. Polyclonal antibodies were followed by treatment with the appropriate FITC conjugate, whereas the monoclonal antibody was followed by treatment with an anti-mouse biotin conjugate and avidin Texas Red. Note the co-localization of vitronectin and fibrin, and the extensive cellularity with which PAI-1 is associated. Bar = 90 mm.
Vitronectin was also found to be associated with In situ hybridization analysis of synovial tissues (Fig. 3 ) demonstrated the presence of vitronectin both macrophage-like and fibroblastoid cells. Its association with macrophage-like cells is shown in Fig. 2 . mRNA in some areas rich in inflammatory cells (Fig. 3a) , but not in connective tissue areas devoid of Figure 2a , c and e shows cells that are positive for vitronectin, most of which are positive for the macroan inflammatory reaction (Fig. 3b) . Collagen mRNA was detected in stromal cells, but not in inflammatory phage markers, mAb M718 (Fig. 2b) , recognizing the CD68 molecule mostly on monocytes and tissue macrocells (Fig. 3c) . Figure 3d depicts some of the areas expressing vitronectin ( V ) or collagen (C ). RNAase phages [27] , or RFD7 (Fig. 2d) , recognizing mature tissue macrophages in rheumatoid arthritic synovia treatment abolished hybridization for both the vitronectin and collagen probes (not shown). [23, 27] . The majority of the vitronectin-positive cells were also stained by antibodies against HLA-DR.
To study further the possible origin and role of the vitronectin found in rheumatoid arthritic synovia, we However, some vitronectin-positive cells were negative for all of these markers and, in addition, negative for isolated the adherent population of cells and metabolically labelled them with [35S]methionine/cysteine. muscle cell and endothelial cell markers. These 'undefined' cells are likely to be fibroblasts, inasmuch
Immunoprecipitation from the conditioned media, with commercially available and previously characterized as some of them stained with two fibroblast markers: the monoclonal antibody 5B5, which recognizes the anti-vitronectin polyclonal antibodies [21] , showed the presence of the 68 kDa polypeptide of vitronectin, as sulphydryl isomerase subunit of prolyl hydroxylase, and the monoclonal antibody to 'fibroblast surface well as a faint 98 kDa band ( Fig. 4) in seven of the 10 isolates studied. protein' (not shown). In a few instances, there were vitronectin-positive cells in the vicinity of blood vessels, Immunoprecipitation of vitronectin-producing isolates with monoclonal antibodies to vitronectin gave but as shown in Figs 2e and f the staining for vitronectin did not delineate blood vessels, in contrast to the the same result as that obtained with the polyclonal antibodies (not shown). As controls for antibody specistaining observed for fibronectin. Figures 2g and h show the background staining obtained with nonficity, the extracts were subjected to immunoprecipitation with anti-fibronectin antibodies and non-immune immune rabbit IgG and mouse IgG, respectively. fibroblast cultures showed low levels of plasmingenerating activity, which could only be detected in As shown in Fig. 5 , plasmin activity can be generated by rheumatoid arthritic synovial cultures and synovial the presence of antibodies to either vitronectin or PAI-1. In contrast, foreskin fibroblast cultures did not fibroblasts, upon addition of exogenous plasminogen in the absence of serum. Figure 5 shows a representatdisplay any detectable plasmin-generating activity, regardless of the addition of antibodies to vitronectin or PAI-1, indicating that there are no artefactual effects of the antibodies themselves in plasmin generation. In the absence of added exogenous plasminogen, no plasmin was generated by any cell type, either in the absence or presence of antibodies to vitronectin or to PAI-1 (not shown). No plasmin-generating activity could be detected in conditioned media alone (not shown), indicating the requirement for cell surface components in the generation of plasmin. In accordance, uPA was detected in cell extracts of synovial cell isolates by immunoprecipitation (not shown).
The ratios of plasmin-generating activity obtained in the presence of the various anti-vitronectin or anti-PAI-1 antibodies, over the activities obtained with control antibodies are depicted in Fig. 6 . In both rheumatoid arthritic synovial cells and fibroblast cul- tures, the monoclonal antibody to vitronectin had the ation remain to be identified. In agreement, a previous study showed that no vitronectin mRNA was present most pronounced effect, inducing a marked increase in plasmin-generating activity. Figure 6A shows the ratios in normal mouse blood cells or lymphoid organs [33] . The expression levels for vitronectin in rheumatoid obtained from a total of seven experiments using five different synovial cell isolates. The monoclonal antisynovia appeared to be similar to those previously demonstrated in advanced astrocytoma [34] . body to vitronectin and the polyclonal antibody to PAI-1 increased plasmin activity by 2.2 (P < 0.01) and
The major site for vitronectin synthesis, under normal physiological conditions, is the hepatocytes 1.5 ± 0.7 (P < 0.05) times, respectively. Neither the polyclonal antibody to vitronectin nor the monoclonal [19] . With a few exceptions, most primary cells [17] , or cell lines [20, 21] , do not synthesize vitronectin in antibody to PAI-1 showed significant effects as compared to the control antibody, or to no antibody. A culture. In the case of the astrocytomas, the upregulation of vitronectin synthesis appears to be dependent total of six experiments were performed with three different synovial fibroblast isolates ( Fig. 6B) , in which on the environment in situ, as cells derived from these tumours do not synthesize vitronectin in culture. In the monoclonal antibody to vitronectin had a dramatic effect, increasing the plasmin-generating activity 11 contrast, we show in this study that the rheumatoid synovial cells are capable of maintaining the signals times over the control. In addition, the polyclonal antibodies to vitronectin and to PAI-1 increased the leading to vitronectin upregulation when cultured in vitro for short periods. plasmin-generating activity in these fibroblast cultures by 3 (P < 0.01) and 1.5 (P < 0.02) times, respectively.
Immunoprecipitation of metabolically labelled rheumatoid synovial cells demonstrated a 68 kDa band, DISCUSSION expected for vitronectin, as well as a faint 98 kDa band whose identity remains to be clarified. The latter In this study we have shown, for the first time, that vitronectin present in rheumatoid synovia is associated band has the expected size for SDS-stable, PAI-1-uPA complexes [35] . Thus, it is conceivable that its with granulation tissue and that synovial cells express vitronectin, both at the mRNA and protein levels. The co-precipitation with anti-vitronectin antibodies arises from some of the vitronectin that remains associated presence of vitronectin in rheumatoid synovia [28] , and in synovial fluid [29] , has previously been reported with PAI-1-PA complexes. The co-precipitation occurred with both polyclonal and monoclonal antias part of studies investigating the presence of various matrix proteins, their receptors, and of inhibitors of bodies to vitronectin, but not with non-immune sera or with antibodies to fibronectin, precluding the poscomplement-mediated cell lysis, respectively. However, neither the cellular origin nor the role of vitronectin sibility of non-specific antibody interactions. Previous findings have indicated that either uPA or tPA can were established in these reports. Two studies [28, 30] reporting the presence of vitronectin in synovia utilize displace vitronectin from PAI-1 [7, 9] . However, this has only been tested in reconstituted systems with a monoclonal antibody (mAb 8E6) that has previously been shown to be polyspecific, recognizing also the isolated proteins. It is possible that in complex systems, given that vitronectin can interact with tPA [36 ] microfibrillar associated protein, MAGP [21] . Thus, stainings with this antibody cannot be attributed to and uPA [37] , vitronectin remains associated with the inhibitor-protease complexes. vitronectin with certainty.
Vitronectin was found to be associated with diverse The ability of anti-vitronectin antibodies to enhance the plasmin-generating activities suggests that vitroneccell populations in the synovia studied. We concluded, based on immunostaining with various cellular tin may maintain PAI-1 activity in this system. If this were the case, it would indicate that the extravascular markers, that most of the vitronectin-positive cells are macrophages and fibroblasts. In a few cases, cells lining or 'cellular' vitronectin is similar to the liver-derived one. Thus, the inhibition of vitronectin function would or present in the vicinity of blood vessels were positive for vitronectin. Even though vitronectin did not outline result in the loss of PAI-1 activity, which would ultimately cause an increase in plasmin-generating capblood vessels in the manner that fibronectin did-by marking the blood vessel basement membranes-this ability. Antibodies to PAI-1 also cause an increase in plasmin-generating activity, but to a lesser extent than localization of vitronectin could be important with regard to the involvement of the vitronectin receptors, the vitronectin antibodies. In particular, the monoclonal antibody to native vitronectin, MaVN, had a the a v b 3 and a v b 5 integrins, in angiogenesis [31, 32] . The cellular association of vitronectin in situ suggests dramatic effect on the plasmin-generating activities of the cells studied. An explanation for the strong effect that the vitronectin found in rheumatoid arthritic tissue arises, at least in part, locally rather than as a result of the anti-vitronectin monoclonal antibody, when compared to the PAI-1 antibodies, could be that: of extravasation of blood components. This was confirmed by in situ hybridization analysis demonstrating (1) the amount of vitronectin synthesized is lower than the amount of PAI-1 and, thus, the amount of antibodthe presence of vitronectin mRNA in infiltrating inflammatory cells. No vitronectin was detected in ies applied might suffice to neutralize vitronectin, but not PAI-1 activity; (2) the monoclonal antibody used non-inflamed synovia, suggesting that cytokines or factors generated during the inflammatory response in this study might interfere with the precise site of vitronectin involved in the modulation of plasmin promote vitronectin synthesis. However, the specific inflammatory signals that direct vitronectin upregulgeneration, i.e. the PAI-1-binding region, whereas the
